UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): August 14, 2015
ROCK
CREEK PHARMACEUTICALS, INC.
(Exact name of registrant as specified
in its charter)
Delaware
(State or other jurisdiction of incorporation) |
000-15324
(Commission File Number) |
52-1402131
(IRS Employer Identification No.) |
2040 Whitfield Avenue, Suite 300
Sarasota, Florida 34243
(Address of principal executive offices,
including zip code)
(804) 527-1970
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. |
Regulation FD Disclosure. |
On August 14, 2015, Rock Creek Pharmaceuticals,
Inc. (the “Company”) issued a press release announcing participation in a conference in New York to be held on September
8-10, 2015. The Company regularly participates in such conferences in the ordinary course of its business. A copy of the press
release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information in this Current Report on
Form 8-K shall not be treated as filed for purposes of the Securities Exchange Act of 1934, as amended.
Item 9.01. |
Financial Statements and Exhibits. |
Exhibit No. |
Description |
99.1 |
Press Release, dated August 14, 2015 |
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
ROCK CREEK PHARMACEUTICALS, INC. |
|
|
|
|
|
By: |
/s/ Michael J. Mullan |
|
|
Michael J. Mullan |
|
|
Chairman of the Board and Chief Executive Officer |
|
|
|
Date: August 14, 2015
Exhibit 99.1
Rock Creek
Pharmaceuticals to Present at the 17th Annual
Rodman &
Renshaw Global Investment Conference
Sarasota, Fl., August 14, 2015 /PRNewswire/ Rock
Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a clinical stage, drug development company which has focused on the
application of its lead compound to chronic inflammatory conditions, announced that the Company will be featured as a
presenting company at the 17th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright &
Co., LLC. The conference is being held September 8-10, 2015, at The St. Regis Hotel in New York City.
Dr. Michael J. Mullan, CEO of Rock Creek Pharmaceuticals, Inc.
will provide an update on the Company during the live presentation and will be available to participate in one-on-one meetings
with investors who are registered to attend the conference.
Event: 17th Annual Rodman & Renshaw
Global Investment Conference
Date: September 10, 2015
Time: 01:45 to 02:10 PM
Location: Louis XVI B (2nd floor); The
St. Regis Hotel
The Rock Creek Pharmaceuticals presentation will also be available
via a live webcast. To access webcast, please click on the following link: http://wsw.com/webcast/rrshq25/rcpi.
The webcast replay will remain available for 90 days following the live presentation.
If you are an institutional investor, and would like to attend
the Rock Creek Pharmaceutical presentation, please click on the following link www.rodm.com
to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the
conference website to request a one-on-one meeting with the management of Rock Creek Pharmaceuticals, inc.
About Anatabine Citrate:
Rock Creek Pharmaceuticals’ compound
is a small molecule, cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics, distinct from other
anti-inflammatory drugs available such as biologics, steroids and non-steroidal anti-inflammatories. The Company has sponsored
extensive pre-clinical (in vitro and in vivo) studies resulting in peer reviewed and published scientific journal articles, covering
models of Multiple Sclerosis, Alzheimer's Disease, and Auto-Immune Thyroiditis. All these studies demonstrated the anti-inflammatory
effects of the Company’s compound. In addition, the Company's compilation of human exposure, safety and tolerability data,
derived primarily from human clinical studies and post-marketing data collection of the previously marketed nutraceutical product,
has provided important insights for clinical development.
About Rock Creek Pharmaceuticals, Inc.:
Rock Creek Pharmaceuticals, Inc. is clinical
stage drug development company focused on the discovery, development and commercialization of new drugs, formulations and compounds
that provide therapies for chronic and acute inflammatory diseases.
For more information, visit: http://www.rockcreekpharmaceuticals.com
Forward Looking Statements:
Certain statements contained in this
release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates,"
"estimates," "intends," "plans," "targets," "projects" and similar expressions.
The statements in this release are based upon the current beliefs and expectations of our company's management and are subject
to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous
factors could cause or contribute to such differences, including, but not limited to, failure to obtain sufficient capital resources
to fund our development program and operations, results of clinical trials and/or other studies, the challenges inherent in new
product development initiatives, including the continued development and approval of anti-inflammatory drug candidates, the effect
of any competitive products, our ability to license and protect our intellectual property, our significant payables, our ability
to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation,
potential litigation by or against us, any governmental review of our products or practices, pending litigation matters, as well
as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation,
our annual report on Form 10-K for the fiscal year ended December 31, 2014 filed on March 12, 2015. We undertake no duty to update
any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
CONTACT:
Ted Jenkins
Vice President, Corporate Strategy & Development
Rock Creek Pharmaceuticals
2040 Whitfield Avenue, Suite 300
Sarasota, FL 34243
Direct: 941-251-0488
tjenkins@rockcreekpharmaceuticals.com
Rock Creek Pharmaceuticals (CE) (USOTC:RCPIQ)
Historical Stock Chart
From Apr 2024 to May 2024
Rock Creek Pharmaceuticals (CE) (USOTC:RCPIQ)
Historical Stock Chart
From May 2023 to May 2024